Annovis Bio to Host Investor Webcast on Buntanetap Developments

Annovis Bio

MALVERN, PAAnnovis Bio Inc. (NYSE: ANVS) will host an investor webcast on July 2, 2024, at 4:30 PM ET to discuss recent progress and future plans for its lead drug candidate, Buntanetap.

The webcast will cover key advancements in the development of Buntanetap, strategic plans for upcoming clinical trials, and an overview of the company’s progress and future direction.

Buntanetap, previously known as Posiphen or ANVS401, targets neurodegeneration. It inhibits the formation of multiple neurotoxic proteins like amyloid beta, tau, alpha-synuclein, and TDP43. By improving synaptic transmission and axonal transport, and reducing neuroinflammation, Buntanetap aims to reverse neurodegeneration in Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and other neurodegenerative conditions.

Investors and interested parties are encouraged to register for the webcast in advance. The registration link is available on the company’s website.

This announcement comes at a crucial time as the company seeks to build investor confidence and outline its roadmap for tackling debilitating neurodegenerative diseases. Attendees will gain insights into how Buntanetap could potentially transform treatment paradigms for AD, PD, and beyond.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.

READ:  Teleflex to Discuss Second Quarter Financials and Operations in August Call